Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus VALISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus VALISONE.
ASMANEX HFA vs VALISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Betamethasone valerate is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), which control the release of arachidonic acid from membrane phospholipids, thereby inhibiting prostaglandin and leukotriene synthesis. It has anti-inflammatory, antipruritic, and vasoconstrictive effects.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum duration: 2 weeks.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Approximately 1.7 hours after topical application; systemic half-life is short due to rapid metabolism.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal (primarily as metabolites, <5% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid